Literature DB >> 11315880

Data requirements in a model of the natural history of Alzheimer's disease.

T J Chaussalet1, W A Thompson.   

Abstract

The "natural history" of Alzheimer's disease (AD) is discussed in terms of the data required in a general, discrete-time, non-homogeneous Markov model. The proposed model differs from similar models reported in the literature because mortality is disaggregated into AD-specific mortality and competing mortality due to other causes. Data are reviewed from the literature for AD incidence, and rates of disease progression and mortality. We conduct a preliminary sensitivity analysis using the reviewed data as base-case. The model shows that survival is sensitive to the modelling assumptions concerning mortality. This observation could have important consequences for studies that assess the cost of care following therapeutic interventions.

Entities:  

Mesh:

Year:  2001        PMID: 11315880     DOI: 10.1023/a:1009689329661

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  24 in total

1.  Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group.

Authors:  C M van Duijn; T Stijnen; A Hofman
Journal:  Int J Epidemiol       Date:  1991       Impact factor: 7.196

2.  The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis.

Authors:  S Gao; H C Hendrie; K S Hall; S Hui
Journal:  Arch Gen Psychiatry       Date:  1998-09

3.  Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.

Authors:  A Stewart; R Phillips; G Dempsey
Journal:  Int J Geriatr Psychiatry       Date:  1998-07       Impact factor: 3.485

4.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.

Authors:  S L Rogers; L T Friedhoff
Journal:  Eur Neuropsychopharmacol       Date:  1998-02       Impact factor: 4.600

5.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

6.  The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

Authors:  L Jönsson; P Lindgren; A Wimo; B Jönsson; B Winblad
Journal:  Clin Ther       Date:  1999-07       Impact factor: 3.393

7.  Natural history of Alzheimer's disease: prognostic value of plateaux.

Authors:  C Piccini; L Bracco; M Falcini; G Pracucci; L Amaducci
Journal:  J Neurol Sci       Date:  1995-08       Impact factor: 3.181

Review 8.  Rate of progression of mental decline in Alzheimer disease: summary of European studies.

Authors:  L Bracco; C Piccini; L Amaducci
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-12       Impact factor: 2.703

9.  The natural history of mental disorder in old age: Alzheimer's disease and depressive illness compared.

Authors:  J R Robinson
Journal:  Int J Geriatr Psychiatry       Date:  1998-09       Impact factor: 3.485

10.  Language impairment and rate of cognitive decline in Alzheimer's disease.

Authors:  M C Goldblum; C Tzortzis; J L Michot; M Panisset; F Boller
Journal:  Dementia       Date:  1994 Nov-Dec
View more
  1 in total

1.  A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Authors:  Stephanie Kirbach; Kit Simpson; Paul J Nietert; Jacobo Mintzer
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.